June 5 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP REPORTS FINAL POSITIVE DATA IN 2ND LINE HEAD AND NECK SQUAMOUS CELL CARCINOMA AT ASCO 2023 ANNUAL MEETING
- IMMUTEP LTD - DUAL IMMUNO-ONCOLOGY APPROACH IS SAFE AND VERY WELL TOLERATED
- IMMUTEP LTD - FOLLOW ON TACTI-003 PHASE IIB TRIAL IN 1ST LINE HNSCC EXPECTED TO REPORT TOP-LINE RESULTS IN H2 OF CY2023
News: IMM Immutep Reports Final Positive Data In 2nd Line Head And Neck Squamous Cell Carcinoma
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.010(4.17%) |
Mkt cap ! $337.6M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 23.0¢ | $244.5K | 1.043M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 392012 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 126850 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |